During the corresponding time, Hyperfine Inc recorded a revenue increase by 67.7 % year on year, sequentially revenue grew by 31.05 %. While revenue at the Hyperfine Inc 's corporate clients
Hyperfine Inc's Comment on Sales, Marketing and Customers
The Swoop® system is primarily utilized within hospital settings, particularly in critical care for both pediatric and adult patients. The company serves multiple healthcare markets, including U.S. hospitals—focusing on critical care units, emergency departments, and hospital-based clinics—U.S. office-based neurology practices, and international healthcare providers through distributor partnerships. Collaborations with leading institutions have been established to gather clinical evidence for various applications such as emergency department imaging, post-operative imaging, office-based neurology, stroke workflows, neurodegenerative screening and monitoring, and care for patients on extracorporeal membrane oxygenation (ECMO). The company maintains a direct commercial presence in the United States and works with third-party distributors in Canada, Europe, Asia, Oceania, and the Middle East as part of a global expansion strategy aimed at increasing access to MR brain imaging in regions with large populations and unmet healthcare needs. The wholly-owned subsidiary Liminal, founded in 2018, suspended its program in December 2022.
Revolutionizing Acute Stroke Care: Hyperfine s Portable MRI Breakthrough On a brisk autumn day in Paris, the city’s heartbeat syncs with the latest innovation in healthcare technology a development poised to revolutionize the acute care landscape for stroke patients across the globe. Hyperfine, Inc. (Nasdaq: HYPR), the audacious health technology company known for pushing boundaries, recently unveiled interim findings on the significant potential of their portable, ultra-low-field Magnetic Resonance Imaging (MRI) system for acute stroke workup. Dubbed the Swoop system, this game-changing device is the first FDA-cleared portable MR brain imaging system, designed to bring high-quality imaging directly to the...
Hyperfine Inc’s Comment on Sales, Marketing and Customers
The Swoop® system is primarily utilized within hospital settings, particularly in critical care for both pediatric and adult patients. The company serves multiple healthcare markets, including U.S. hospitals—focusing on critical care units, emergency departments, and hospital-based clinics—U.S. office-based neurology practices, and international healthcare providers through distributor partnerships. Collaborations with leading institutions have been established to gather clinical evidence for various applications such as emergency department imaging, post-operative imaging, office-based neurology, stroke workflows, neurodegenerative screening and monitoring, and care for patients on extracorporeal membrane oxygenation (ECMO). The company maintains a direct commercial presence in the United States and works with third-party distributors in Canada, Europe, Asia, Oceania, and the Middle East as part of a global expansion strategy aimed at increasing access to MR brain imaging in regions with large populations and unmet healthcare needs. The wholly-owned subsidiary Liminal, founded in 2018, suspended its program in December 2022.
Sources:
Hyperfine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Hyperfine Inc’s corporate clients.
For your research, we’ve provided 9 tables on Hyperfine Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
164.63 %